Profound Medical moves Plymale to COO, taps ex-Novadaq CEO Menawat Profound Medical said yesterday it is transitioning its current CEO Steven Plymale to the position of chief operating officer and picking up former Novadaq CEO Arun Menawat to take over the corner office. Menawat has held a position as a board member with Profound […]
Royal Philips (NYSE:PHG) said it extended its deal with Profound Medical to include a sales and marketing agreement to promote Profounds’ Tulsa-Pro ultrasound ablation system. Profounds Tulsa system allows for a minimally invasive, whole-gland ablation of the prostate, which will be guided by Philips MRI machines, the companies said. “Our agreement with Philips will enable us to […]
Profound Medical said today it won CE Mark approval in the European Union for its Tulsa-Pro ablation device designed to treat prostate cancer. The Toronto-based company’s system allows for a minimally invasive, whole-gland ablation of the prostate, guided by magnetic resonance imaging machines, the company said. “Our innovation and passion for this unique therapy has […]
EnteroMedics (NSDQ:ETRM) said it named Dan Gladney, the former chief executive who led Lanx to an acquisition by Biomet, to be its new CEO effective Nov. 16. St. Paul, Minn.-based EnteroMedics said chairman, president & CEO Mark Knudson will become executive chairman when Gladney takes over the corner office until Jan. 1, 2016, when he will […]
Royal Philips (NYSE:PHG) said it signed a deal with Profound Medical to use Profound’s proprietary transurethral ultrasound ablation technology to treat prostate cancer patients in conjunction with Philips’ Ingenia and Achieva 3 tesla MRI systems. Profounds ‘Tulsa’ system allows for a minimally invasive, whole-gland ablation of the prostate, which will be guided by Philips MRI machines, […]
April 30, 2015 by Brad Perriello
Profound Medical yesterday said it’s slated to hit the public markets in Canada after a reverse merger, also revealing a $24 million private placement to fuel clinical trial work.
Versant Ventures and James Mazzo agreed that Mazzo will "suspend any activities" at the venture capital shop following his indictment last month on insider trading charges.
Profound Medical said it won an investigation device exemption from the FDA for a clinical trial of its device to treat prostate cancer.
The Toronto-based medical device company said it hopes to begin enrolling patients later this year in the Tulsa trial.
The Profound device combines thermal ultrasound with real-time MRI guidance in a single outpatient session to treat localized prostate cancer, according to a press release.